UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): May 30, 2012 (May 30, 2012)

 

 

Valeant Pharmaceuticals International, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Canada   001-14956   98-0448205

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S Employer

Identification No.)

4787 Levy Street,

Montreal, Quebec

Canada H4R 2P9

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (514) 744-6792

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 30, 2012 the Company held its Annual Meeting. At the Annual Meeting, the shareholders of the Company voted on the following six proposals, each of which is described in detail in the Proxy Statement. The results of each matter voted upon are as follows:

Proposal No. 1: Election of Directors. The following individuals were elected to the Company’s Board of Directors:

 

Name

   For      Withheld      Broker Non-Votes  

Ronald Farmer

     238,259,900         432,533         19,260,347   

Robert A. Ingram

     234,611,761         4,080,672         19,260,347   

Theo Melas-Kyriazi

     237,422,145         1,270,288         19,260,347   

G. Mason Morfit

     238,069,970         622,463         19,260,347   

Laurence E. Paul

     237,948,717         743,716         19,260,347   

J. Michael Pearson

     232,764,713         5,927,720         19,260,347   

Robert N. Power

     238,099,133         593,300         19,260,347   

Norma A. Provencio

     237,424,311         1,268,122         19,260,347   

Lloyd M. Segal

     238,226,188         466,245         19,260,347   

Katharine B. Stevenson

     237,329,728         1,362,705         19,260,347   

Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.

 

For

  

Against

  

Abstain

  

Broker Non-Votes

228,874,096

   9,163,249    655,088    19,260,347

Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed the PricewaterhouseCoopers LLP (United States) as the Company’s independent registered public accounting firm to serve until the close of the 2013Annual Meeting of Shareholders and authorized the Board of Directors to fix the auditors’ remuneration.

 

For

  

Withhold

  

Broker Non-Votes

254,034,665

   3,918,115    0


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

VALEANT PHARMACEUTICALS

INTERNATIONAL, INC.

Date: May 30, 2012     By:   /s/ Robert Chai-Onn
      Robert Chai-Onn
      Executive Vice President, General Counsel